Setting 
My Cart

Ordered before 17:30, shipped today - Support: (012) 800 456 789

Track Your Order

Toggle Nav
mobile icon
Close
  • Menu
  • Setting
  • Home
  • Search results for: 'research area cell cycle c myc'

Search results for: 'research area cell cycle c myc'

Items 11-20 of 101

Page
per page
  1. Regorafenib hydrochloride
    A3750 Regorafenib hydrochloride
    Target: Raf|VEGFR|PDGFR|c-Kit|c-RET
    Summary: Tyrosine kinase inhibitor
      ≥25.95 mg/mL
  2. TG101209
    A4145 TG101209
    Summary: JAK2/3 inhibitor
      ≥25.5 mg/mL
  3. Regorafenib
    A8236 Regorafenib
     4 Citation
    Target: Raf|VEGFR|PDGFR|c-Kit|RET
    Summary: Inhibitor of VEGFR/PDGFR/FGFR/mutant kit/RET/Raf-1
      ≥25.04 mg/mL
  4. Ki20227
    A3527 Ki20227
    Target: c-Fms tyrosine kinase
    Summary: C-Fms tyrosine kinase inhibitor
      ≥48.1 mg/mL
  5. Pazopanib Hydrochloride
    A8347 Pazopanib Hydrochloride
    Summary: VEGFR/PDGFR/FGFR/c-Kit/ c-Fms inhibitor
      ≥11.1 mg/mL
  6. Golvatinib (E7050)
    B1439 Golvatinib (E7050)
    Target: VEGFR
    Summary: C-Met/VEGFR-2 inhibitor
  7. PHA-665752
    A2307 PHA-665752
     1 Citation
    Target: c-MET
    Summary: C-Met inhibitor,potent and ATP-competitive
  8. PF-04217903 methanesulfonate
    A3712 PF-04217903 methanesulfonate
    Target: c-MET
    Summary: C-Met inhibitor,selective and ATP-competitive
      Soluble in DMSO
  9. (R)-Crizotinib
    A3020 (R)-Crizotinib
     2 Citation
    Target: c-MET
    Summary: C-MET/ALK inhibitor,potent and ATP-competitve
      insoluble in H2O; insoluble in EtOH; ≥7.51 mg/mL
  10. Tivantinib (ARQ 197)
    A8325 Tivantinib (ARQ 197)
     2 Citation
    Target: MET
    Summary: C-Met inhibitor,non-ATP-competitive
      ≥18.47 mg/mL

Items 11-20 of 101

Page
per page
Shop By
Now Shopping by
  1. Category Tyrosine Kinase Remove This Item
Clear All
Shopping Options
Category
  1. Bcr-Abl 7item
  2. Axl 2item
  3. ALK 5item
  4. Broad Spectrum Protein Kinase Inhibitor 2item
  5. c-FMS 1 item
  6. c-Kit 7item
  7. c-MET 18item
  8. c-RET 7item
  9. EGFR 13item
  10. FAK 2item
  11. FGFR 5item
  12. FLT3 9item
  13. HER2 2item
  14. IGF1R 1 item
  15. Insulin Receptor 1 item
  16. Lck 1 item
  17. LRRK2 2item
  18. PDGFR 12item
  19. Pyk2 1 item
  20. ROR 2item
  21. Spleen Tyrosine Kinase (Syk) 3item
  22. Src 7item
  23. Tie-2 2item
  24. Trk 4item
  25. VEGFR 19item
Specificity
  1. Selective 41item
Reversibility
  1. Reversible 2item
  2. Irreversible 2item
Target
  1. Cyclin-Dependent Kinases 1 item
  2. Raf 4item
  3. Aurora Kinases 1 item
  4. CSF-1R 1 item
  5. FLT3 4item
  6. Eph Receptors 1 item
  7. VEGFR 18item
  8. PDGFR 13item
  9. c-Kit 10item
  10. RET 1 item
  11. Bcr-Abl 4item
  12. FGFR 4item
  13. MET 5item
  14. Src 4item
  15. Trk Receptors 3item
  16. EGFR 7item
  17. FAK 1 item
  18. Syk 1 item
  19. ErbB 2item
  20. c-MET 7item
  21. PKC 1 item
  22. Ca2 /calmodulin-dependent protein kinases (CaMKs) 1 item
  23. Lyn 1 item
  24. LRRK2 2item
  25. ALK 1 item
  26. Tie-2 2item
  27. Ron 1 item
  28. c-Fyn 1 item
  29. c-RET 1 item
  30. c-Fms tyrosine kinase 1 item
  31. insulin 1 item
  32. DCLK2 1 item
Reported Experiments
  1. Animal Experiments 52item
  2. Cell Experiments 39item
Related Disease
  1. Acute Myeloid Leukemia 1 item
  2. Adrenocortical Carcinoma 1 item
  3. Autoimmune Diseases 1 item
  4. Bladder Cancer 3item
  5. Bladder Carcinoma 1 item
  6. Breast Cancer 9item
  7. Cancer 42item
  8. Cholangiocarcinoma 1 item
  9. Clear Cell Renal Cell Carcinoma 1 item
  10. Colon Cancer 1 item
  11. Colon Carcinoma 1 item
  12. Colorectal Cancer 8item
  13. Glioblastoma 5item
  14. Glioma 1 item
  15. Hepatocellular Carcinoma 1 item
  16. Leukemia 1 item
  17. Liver Cancer 2item
  18. Lung Cancer 3item
  19. Lung Carcinoma 2item
  20. Lymphoma 1 item
  21. Melanoma 1 item
  22. Multiple Myeloma 1 item
  23. Non-small Cell Lung Cancer 2item
  24. Ovarian Cancer 2item
  25. Pancreatic Cancer 8item
  26. Prostate Cancer 6item
  27. Renal Cell Carcinoma 3item
  28. Thyroid Cancer 2item